Close menu




Pharma

Photo credits: pixabay.com

Commented by André Will-Laudien on May 20th, 2025 | 07:10 CEST

Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review

  • Biotechnology
  • Biotech
  • Pharma

With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!

Read

Commented by Armin Schulz on May 14th, 2025 | 07:00 CEST

Patents, partnerships & tumor strategies: How Novo Nordisk, BioNxt Solutions, and BioNTech are securing tomorrow's profits

  • Biotechnology
  • Biotech
  • Pharma

The global pharmaceutical industry, once the epitome of stable investments, is undergoing radical change. While protectionist trade barriers are disrupting supply chains and causing stock market prices to plummet, companies are forecasting growth for the biotech and pharmaceutical industries, according to the industry study "Life Sciences Executives Flash Report." The crisis is turning out to be a laboratory of opportunities – those who prioritize digital therapies, mRNA technologies, or sustainable production models now could emerge as winners in a reorganized market. But which strategies are convincing? We take a closer look at Novo Nordisk, BioNxt Solutions, and BioNTech.

Read

Commented by Nico Popp on May 13th, 2025 | 07:10 CEST

The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma

Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.

Read

Commented by Armin Schulz on May 8th, 2025 | 07:05 CEST

Cancer revolution: How Bayer, Vidac Pharma, and Pfizer are shaking up the billion-dollar market

  • Biotechnology
  • Biotech
  • Pharma

Oncology has become the scene of an unprecedented competition. Where billion-dollar markets meet life-saving innovations, a global playing field for pioneers is emerging. Forecasts show that therapy costs and market volume are growing exponentially. This poses a challenge for healthcare systems and represents a gold mine for visionaries. New technologies such as personalized cancer vaccines and targeted drugs are pushing the boundaries of what is possible. Three players are strategically positioning themselves in this dynamic environment: Bayer, Vidac Pharma, and Pfizer. Their next moves could shape not only patients' lives, but entire industries.

Read

Commented by Armin Schulz on May 7th, 2025 | 07:10 CEST

Evotec's AI gold mine, Defence Therapeutics' billion-dollar markets, Novo Nordisk's diet revolution: How investors are profiting

  • Biotechnology
  • Biotech
  • AI
  • Pharma

The healthcare industry is undergoing radical change. Algorithms are accelerating drug discovery by years, billions are being poured into personalized therapies, and biotech stocks are celebrating on the stock markets. But this time, it is not just short-lived hype – the next era of medicine will be shaped by companies merging technology and biology. While AI-based platforms identify drug candidates in record time, pioneers are pushing ahead with groundbreaking approaches in oncology, immunology, and metabolic diseases. Three names stand out: Evotec, Defence Therapeutics, and Novo Nordisk.

Read

Commented by Armin Schulz on May 6th, 2025 | 07:05 CEST

Soil boosters wanted! The secret weapons of Bayer, Argo Living Soils, and K+S

  • Pharma
  • fertilizer
  • Agriculture
  • Technology

Agriculture is at a crossroads between tradition and revolution. While optimistic forecasts like the Iowa Crop Progress Report 2025 predict record-breaking harvests, a paradoxical conflict is emerging. Blooming fields conceal depleting soils and climate stress. But this is precisely where the tension for innovation unfolds - where high-tech meets sustainability. Three players are helping to shape this future: Bayer as a pioneer of digital agricultural solutions; Argo Living Soils with revolutionary soil savers; and K+S, which is rethinking mineral fertilizers. Together, they are not only securing harvests but also healing ecosystems.

Read

Commented by André Will-Laudien on May 5th, 2025 | 07:20 CEST

Biotech is back with artificial intelligence! Evotec, NetraMark Holdings, Bayer, and BioNTech

  • Biotechnology
  • Biotech
  • Pharma

Artificial intelligence has arrived in health research! Whenever large volumes of data need to be analyzed, patterns recognized, or results condensed, immense computing power is required. The goal is to detect complex structures, automate processes, and make real-time decisions. The use of AI in medicine and pharmaceutical development is making good progress because time and high validation capability are key here. Some companies have already recognized the signs of the times and are working hard on the new technologies. On the stock market, this is often the starting signal for significantly higher valuations. Evotec, Bayer, and BioNTech are well-known European players, while Canadian company NetraMark Holdings has seen its share price increase sevenfold since fall 2024. What is behind this surge?

Read

Commented by Fabian Lorenz on May 1st, 2025 | 07:10 CEST

A bombshell at Nel ASA! Buying opportunity for Bayer and Defence Therapeutics shares?

  • Biotechnology
  • Biotech
  • renewableenergies
  • Pharma

A bombshell at Nel ASA. The hydrogen specialist has reported its first quarter results: revenue and order intake are down, while the Company is sliding deep into the red. Will new major shareholder Samsung bring about a turnaround? Defence Therapeutics is a hot rebound candidate with takeover speculation. The biotech company is consistently pushing ahead with the monetization of its technology and has found a strong partner. The decline in the share price in recent months offers opportunities. A lot of negative news is certainly already priced into Bayer's share price, but is that enough to buy the stock? Yes, according to analysts.

Read

Commented by Fabian Lorenz on April 30th, 2025 | 07:15 CEST

Buy BioNTech after the crash? Valneva with vaccine problems! Vidac Pharma shares show potential!

  • Biotechnology
  • Biotech
  • Pharma

BioNTech shares crashed by around 10% on Friday. So far, they have not been able to recover. What caused the setback? Should investors seize the opportunity? Analysts believe the German biotech heavyweight is on track. The same applies to Vidac Pharma. The news flow is extremely positive, but the stock is not making any headway. Analysts believe that Vidac shares could multiply in value. If the biotech company continues to be successful, a takeover could follow. And what is going on at Valneva? The stock is on a rollercoaster ride. Could a vaccine become a problem?

Read

Commented by Nico Popp on April 25th, 2025 | 07:20 CEST

US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma

The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?

Read